<DOC>
	<DOCNO>NCT01293006</DOCNO>
	<brief_summary>This study evaluate safety , tolerability , effect multiple dos suvorexant ( MK-4305 ) respiratory function participant chronic obstructive pulmonary disease ( COPD ) . This crossover study , participant receive suvorexant placebo study . The primary hypothesis study multiple dos suvorexant produce clinically significant reduction mean oxygen saturation ( SaO2 ) total sleep time participant COPD , compare placebo .</brief_summary>
	<brief_title>Effects Suvorexant Patients With Chronic Obstructive Pulmonary Disease ( MK-4305-032 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Suvorexant</mesh_term>
	<criteria>Female participant reproductive potential must demonstrate serum betahuman chorionic gonadotropin ( βhCG ) level consistent nongravid state prestudy ( screen ) visit agree use ( and/or partner use ) two ( 2 ) acceptable method birth control begin prestudy visit throughout study ( include washout interval treatment periods/panels ) 2 week last dose study drug last treatment period . Females nonchildbearing potential ( postmenopausal without menses least 1 year follicle stimulate hormone [ FSH ] value postmenopausal range , status post hysterectomy , oophorectomy tubal ligation . Documented hysterectomy oophorectomy ) Body Mass Index ( BMI ) ≤40 kg/m2 prestudy ( screen ) COPD document medical history pulmonary function test spirometry measurement Visit 1 meet follow COPD study criterion accord modify Global Initiative Obstructive Lung Disease ( GOLD ) criterion ( forced expiratory volume [ FEV1 ] / force vital capacity [ FVC ] ratio ≤70 % FEV1 ≥40 % predict [ inclusive ] ) Stable physical health least 2 week prior enter study No clinically significant abnormality electrocardiogram ( ECG ) No clinically significant abnormality screen polysomnography ( PSG ) include evidence obstructive sleep apnea , restless leg syndrome , periodic limb movement disorder , parasomnia include nightmare disorder , sleep terror disorder sleepwalk disorder participant insomnia may enrol Nonsmoker smoke ≤20 cigarette equivalent per day without urge wake smoke night Sleeps 4 hour per night usual bedtime 8:00 post meridian ( PM ) 12:30 ante meridian ( AM ) Participant must complete sleep diary least 5 consecutive day 21 day prior screen PSG visit Participant reliably able perform study assessment ; demonstrate ability understand task instruction , physically capable Participant mentally legally incapacitate , significant emotional problem time prestudy expect conduct study , history evidence clinically significant psychiatric disorder would interfere participation study Abnormal prerandomization laboratory value alanine transaminase ( ALT &gt; 1.5 x upper limit normal [ ULN ] ) , aspartate transaminase ( AST &gt; 1.5 x ULN ) , total bilirubin &gt; 1.5 x ULN , serum creatinine &gt; 2 mg/dL Participant history neurological disorder , include limited seizure disorder ( single episode childhood febrile seizure ) , stroke , transient ischemic attack , multiple sclerosis , cognitive impairment , significant head trauma sustain loss consciousness within last 10 year History bipolar disorder , psychotic disorder , posttraumatic stress disorder , psychiatric condition require treatment prohibit medication , psychiatric condition , investigator 's opinion , would interfere patient 's ability participate study Participant COPD evidence another clinically significant , active pulmonary disorder , bronchiectasis asthma document history , physical examination , chest x‑ray History within past 6 month prior prestudy acute coronary syndrome , unstable angina , congestive heart failure , cardiogenic syncope , cardiomyopathy , symptomatic arrhythmia , orthostatic hypotension , uncontrolled hypertension History neoplastic disease except adequately treat nonmelanomatous skin carcinoma carcinoma situ cervix , malignancy successfully treat ≥10 year prior prestudy followup reveal evidence recurrence time treatment time prestudy , opinion Investigator , highly unlikely sustain recurrence duration study History diagnosis narcolepsy , cataplexy ( familial idiopathic ) , circadian rhythm sleep disorder , parasomnia include nightmare disorder , sleep terror disorder , sleepwalk disorder , REM behavior disorder , sleeprelated Breathing Disorder ( i.e. , obstructive central sleep apnea syndrome central alveolar hypoventilation syndrome ) , periodic limb movement disorder , restless legs syndrome , primary hypersomnia Normal PSG record screen Hematocrit &gt; 55 % Participant treat emergency room hospitalize COPD within 2 month prior screen visit , necessitate antibiotic , systemic corticosteroid , oxygen therapy Positive screening urine alcohol test drug test Nursing mother Condition , therapy , lab , ECG abnormality circumstance might confound result study Taking , plan take , one prohibit concomitant medication Participant consumes excessive amount alcohol , define great 3 glass alcoholic beverage , excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , caffeinated beverage per day Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 4 week prior prestudy ( screen ) visit History significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food Currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 2 year Need 3 toilet visit night Participant history shift work ( defined permanent night shift rotate day/night shift work ) within past 2 week anticipates need perform shift work study Travel across 3 time zone ( transmeridian travel ) within 1 week study start Participant imminent risk selfharm harm others investigator 's opinion Concerns investigator regard safe participation participant study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pulmonary Disease , Chronic Obstructive</keyword>
</DOC>